IQ Reddit Mentions | ChartExchange

The CMS 2027 Advance Notice and the recent OIG reports are out and I think most of the sector is completely missing the "cliff" that was just built for legacy insurers.
The headline we saw this week was the **0.09% benchmark rate increase**. Everyone saw that as a "sector headwind." But if you actually read the technicals, CMS just lit a fire under every insurer that isn’t using point-of-care AI.
# 1. The Death of the "Chart Review" (The -1.53% Hit)
Starting in 2027, CMS is proposing to **completely exclude diagnoses from "unlinked" chart reviews.** \* **The Context:**Big insurers (UNH, HUM, etc.) have made billions by hiring vendors to dig through old paper charts to find codes they can bill for after the fact. This is "unlinked" because it’s not tied to an actual doctor-patient visit.
* **The Hammer:** CMS projects this change alone will slash MA risk scores by **1.53% ($7.1 Billion total)**.
* **The Clover Edge:** Counterpart Assistant is **Synchronous Point-of-Care.** Every code it finds is "linked" by definition because the doctor clicks "agree" while the patient is sitting in the chair. Clover’s revenue is audit-proof and compliant by design, while the "old guard" is looking at a massive revenue hole they literally can't fill without a tool like Counterpart.
# 2. V28 is an IQ Test, and Legacy is Failing
We are moving fully into the **V28 Risk Model** for 2026/2027. V28 removed roughly 2,000 "junk codes" and replaced them with high-specificity requirements.
* Legacy insurers are struggling because you can't find "specificity" in an old, messy chart from six months ago.
* Clover’s HEDIS clinical score is **4.72** (for the PPO). That isn't just a number; it’s proof that the AI is finding the specific V28 chronic conditions (CKD, COPD, etc.) *while* there's time to treat them. This is the only way to maintain a high RAF (Risk Adjustment Factor) under the new rules.
# 3. The 53% Growth Paradox
A lot of people are shrugging off the **53% membership growth** because they think "growth = higher MCR." But look at the mechanism:
* Clover is growing in high-ADI (Area Deprivation Index) populations—the ones the big guys are running away from.
* Why? Because if you have the AI to manage these patients from Day 1, they are actually the **most profitable** cohort because the "delta" for improvement is so high.
* The market thinks Clover is taking on "bad risk." I think Clover is the only one who has the "germ theory" (AI) to make that risk profitable while the rest of the industry is still using leeches.
# 4. The "Forced Adoption" of Counterpart
This is the big one. If you are a mid-sized plan and you just saw your "unlinked" revenue get nuked for 2027, you have two choices:
1. Die on the vine.
2. License a point-of-care tool that actually works.
Clover is essentially selling a **Compliance-as-a-Service** platform. They don't have to "sell" outcomes anymore (even though they have them); they just have to sell **survival**.
# Bottom Line:
We are in a massive "sentiment vacuum" because the market is pricing Clover as a "struggling insurer" in a "bad sector." They haven't realized that the **sector's failure is Counterpart's catalyst.** The 0.09% rate notice wasn't a warning for Clover; it was a subpoena for the rest of the industry to start washing their hands with AI. If the Q4 report shows even a hint of GAAP profitability while scaling 53%, the "shrug" is going to turn into a scramble real fast.
\*AI polished this and formatted it, but the facts remain.

.dark-mode .zSKdsP{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .zSKdsP{ color: #333333; background-color: white; border: 2px solid #333333; }IQiQIYI, Inc.stock NASDAQ ADR

IQ
iQIYI, Inc.
stock NASDAQ ADR